number of downloads : ?
language
eng
Author
Sakurai, Yuuichi Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Takabayashi, Nobuyoshi Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Kudou, Kentaro Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Araki, Takahiro Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
Miyagi, Takuya Department of Internal Medicine, Fukuyama Daiichi Hospital, Hiroshima, Japan
Iwakiri, Katsuhiko Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Ashida, Kiyoshi Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Journal Title
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
Volume
10
ISSN
2155-384X
Published Date
2019-11
DOI
PubMed ID
Publisher
LIPPINCOTT WILLIAMS & WILKINS
NII Type
Journal Article
OAI-PMH Set
Faculty of Medicine
Remark
This study was sponsored by Takeda Pharmaceutical Company Limited, manufacturer/licensee of Takecab or Vocinti. Takeda Pharmaceutical Company Limited was involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Thao Le, MD, PhD, and Tania Dickson, PhD, CMPP, of ProScribe-Envision Pharma Group and was funded by Takeda Pharmaceutical Company Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3). Ethical approval and informed consent: The study was registered (ClinicalTrials.gov: NCT02954848), approved by the local institutional review board, and conducted at 44 study sites in Japan in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guideline for Good Clinical Practice, and applicable Japanese regulations. All patients signed the informed consent form before participation.